50% Off! Beat the market in 2025 with InvestingProCLAIM SALE

Guardant Health director Tariq Musa sells $4,042 in common stock

Published 20/12/2024, 00:32
Guardant Health director Tariq Musa sells $4,042 in common stock
GH
-

PALO ALTO, Calif.—Tariq Musa, a director at Guardant Health , Inc. (NASDAQ:GH), recently sold a portion of his holdings in the company. According to a recent filing, Musa disposed of 116 shares of the company’s common stock at a price of $34.85 per share, totaling approximately $4,042. The transaction comes as the stock has experienced a notable 10.9% decline over the past week, according to InvestingPro data. Following this transaction, Musa retains ownership of 2,810 shares in the company. The sale was executed on December 18, 2024, and was reported to the Securities and Exchange Commission the following day. The company, currently valued at $3.87 billion, maintains strong liquidity with a current ratio of 6.22 and has achieved impressive revenue growth of 29.2% over the last twelve months. InvestingPro subscribers have access to 8 additional key insights and a comprehensive Pro Research Report, which provides detailed analysis of Guardant Health’s financial health, which is currently rated as GOOD.

In other recent news, Guardant Health, a precision oncology company, has revealed a collaboration with pharmaceutical firm Boehringer Ingelheim. The partnership aims to secure regulatory approval for Guardant360® CDx, a liquid biopsy test, as a companion diagnostic for zongertinib, an investigational drug for non-small cell lung cancer. Over the last twelve months, Guardant Health has seen a notable revenue growth of 29.2%.

The Guardant360 CDx test identifies patients with HER2 mutations in NSCLC who may benefit from zongertinib. This test is the first FDA-approved comprehensive liquid biopsy for all advanced solid tumors and has wide commercial and Medicare coverage. The collaboration is expected to facilitate oncologists in identifying advanced lung cancer patients suitable for treatment with zongertinib.

Guardant Health has also reported its financial results for the third quarter of 2024. While no specific financial details were disclosed, the absence of reported financial misses suggests that the company may have met its quarterly expectations. These recent developments highlight Guardant Health’s ongoing efforts to provide accurate financial reporting and transparency to its investors.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2024 - Fusion Media Limited. All Rights Reserved.